Medivo and NeoGenomics Laboratories Announce Lab Data Analytics Partnership
NEW YORK, N.Y. (PRWEB) September 23, 2014 -- Sept. 23, 2014 -- Medivo, Inc., a leader in lab data analytics, today announced that it has partnered with NeoGenomics Laboratories, a leading provider of cancer-focused genetic and molecular testing services, for a data analytics collaboration.
This collaboration enables NeoGenomics to realize new value in its lab data by participating in the Medivo Lab Value Exchange ™ (LVX™). Medivo’s LVX is the largest aggregation of standardized and anonymized lab test results available in the market today, and contains data from 200,000 practice locations and 30 million patients. Medivo’s LVX provides unique actionable insights into lab testing trends for use by researchers, life science companies and clinical laboratories.
"We are excited to sign this partnership with the specialty lab NeoGenomics, which provides the latest testing technologies and valuable interactive education to the pathology community," said Sundeep Bhan, Chief Executive Officer and a Co-Founder of Medivo. "NeoGenomics’ comprehensive oncology testing menu will help us expand Medivo’s LVX database, enabling us to work more effectively with our partners to better inform treatment decisions and improve health outcomes.”
NeoGenomics Laboratories is a specialized oncology reference laboratory providing the latest testing technologies through a nationwide network of laboratories, including a complete spectrum of diagnostic services in immunohistochemistry, FISH, flow cytometry, cytogenetics and molecular testing. Board-certified pathologists and specially trained cancer genetic professionals lead the NeoGenomics medical team.
“This collaboration with Medivo will help us explore new opportunities for our data assets and enhance our outreach to the pathology community,” said Douglas M. VanOort, Chairman and Chief Executive Officer of NeoGenomics. “It also allows us to contribute to the effort to improve the delivery of appropriate treatments to patients.”
NeoGenomics, in July 2014, launched 23 innovative NeoTYPE™ Cancer Profiles that are based on next-generation sequencing (NGS). The advanced cancer-profiling tools offer oncologists and pathologists a more targeted and comprehensive ability to tailor cancer testing to an individual patient's needs than previously had been possible.
NeoGenomics’ comprehensive oncology menu, incorporated into Medivo’s LVX database, will provide Medivo’s partners with a superior resource for research and discovery of new insights in oncology conditions, in an effort to improve patient outcomes.
About Medivo
Medivo unlocks the power of lab data to better inform treatment decisions and improve health outcomes. Medivo's clinical data experts extract proprietary insights from the Medivo Lab Value Exchange™(LVX™), an anonymized patient level clinical database from a network of more than 140 U.S. labs with data across 200,000 practice locations and 30 million patients. Medivo helps deliver on the promise of personalized medicine by providing decision support on the use of targeted therapeutics. Medivo enables life science companies to build clinical intelligence to optimize their sales and marketing initiatives. Medivo's services enable its clinical lab partners to realize the full value of their data assets. Founded in 2010 by healthcare entrepreneurs, Medivo's investors include Safeguard Scientifics, Inc. (NYSE:SFE) and Merck Global Health Innovation Fund (GHIF). For more information, visit http://www.medivo.com.
About NeoGenomics
NeoGenomics, Inc. is a CLIA–certified clinical laboratory that specializes in cancer genetics testing, the fastest-growing segment of the laboratory industry. The Company’s testing services include cytogenetics, fluorescence in-situ hybridization (FISH), flow cytometry, immunohistochemistry, anatomic pathology and molecular genetic testing. Headquartered in Fort Myers, FL, NeoGenomics has laboratories in Nashville, TN, Irvine, Fresno and West Sacramento CA, Tampa and Fort Myers, FL. NeoGenomics services the needs of pathologists, oncologists, other clinicians and hospitals throughout the United States. For more information, visit http://www.neogenomics.com/
Mark Tosh, Medivo, +1 (201) 532-4062, [email protected]
Share this article